<DOC>
	<DOC>NCT01390428</DOC>
	<brief_summary>This study will compare the pharmacokinetics (PK) of grazoprevir (MK-5172) when administered to participants with mild, moderate or severe hepatic insufficiency (assessed by the criteria of the Child-Pugh's scale) with the PK of grazoprevir when administered to healthy participants.</brief_summary>
	<brief_title>Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>If female, must be of nonchildbearing potential or willing to use at least 2 acceptable methods of contraception from enrollment to 2 weeks after the last dose of study drug No clinically significant abnormality on electrocardiogram Hepatic Insufficiency Participants Only: Other than hepatic insufficiency with features of cirrhosis, is otherwise in good health based on medical history, physical examination, vital signs, and laboratory safety tests Chronic (&gt;6 months), stable (no acute episodes of illness within the previous 2 months due to deterioration in hepatic function) hepatic insufficiency with features of cirrhosis due to any etiology Score on the ChildPugh scale must range from 5 to 6 (mild hepatic insufficiency) to from 7 to 9 (moderate hepatic insufficiency) to from 10 to 15 (severe hepatic insufficiency) Matched Healthy Participants Only: In good health based on medical history, physical examination, vital signs, and laboratory safety tests History of any illness that might confound the results of the study or poses an additional risk to the participant History of clinically significant endocrine, gastrointestinal (other than related to their hepatic impairment), cardiovascular, hematological, immunological, renal, respiratory, or genitourinary abnormalities or diseases Pregnancy Estimated creatinine clearance of â‰¤60 mL/min History of stroke, chronic seizures, or major neurological disorder History of neoplastic disease (including leukemia, lymphoma, malignant melanoma), or myeloproliferative disease, regardless of the time since treatment Unable to refrain from or anticipates the use of any medication, including prescription and nonprescription drugs or herbal remedies (such as St. John's Wort, green tea, gingko, coenzyme Q, ginseng, echinacea, etc.) or nutritional supplements (e.g., garlic supplements), beginning approximately 2 weeks (or 5 halflives) prior to administration of the initial dose of study drug, throughout the study, until the poststudy visit Participated in another investigational study within 4 weeks History of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or nonprescription drugs or food Hepatic Insufficiency Participants Only: Has a history of hepatitis C infection by serology, regardless of most recent viral load status. Matched Healthy Participants Only: History of any chronic and/or active hepatic disease including elevations of serum transaminases, hepatitis, biliary tract disease, or a history of any significant gastrointestinal surgery. History of hepatitis C. Participants with a history of selflimited hepatitis A with complete resolution documented at least 6 months prior to entry will be eligible for inclusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>